Loading page
Loading page
Loading substance route
Chronic use is considered moderately addictive with a high potential for abuse and is capable of producing psychological dependence among certain users. Compulsive redosing has been reported. When addiction develops, cravings and withdrawal effects may occur upon cessation.
The lethal dosage of HXE is not known. The substance has very little history of human usage and its toxicity has not been studied in any scientific context.
Mania can potentially occur in users who are compulsively and regularly consuming large amounts. This effect occurs less often with HXE than with more stimulating dissociatives such as 3-MeO-PCP or 2'-Oxo-PCE.
HXE was first identified as an active metabolite of methoxetamine (MXE), the dissociative arylcyclohexylamine that preceded it on research chemical markets. Interest in HXE as a standalone substance developed within research chemical communities, with initial announcements about its potential…
Controlled as a specially defined derivative of PCE or O-PCE under Swiss narcotics legislation. Production, possession, and distribution are prohibited.
Not explicitly scheduled under the Controlled Substances Act. However, possession or distribution may be prosecuted under the Federal Analogue Act when intended for human consumption, as HXE is structurally related to scheduled arylcyclohexylamines. Products labeled 'not for human consumption' attempt to circumvent this provision.
Controlled substance. As an arylcyclohexylamine with psychoactive properties, it likely falls under the Psychoactive Substances Act 2016, which prohibits the production, distribution, and possession with intent to supply of psychoactive substances.
17 sources cited